Noona Healthcare Locks Leading Academic Partnership to Launch Study on Long-Term Tolerability of Cancer Immuno-Oncology Therapies
PALO ALTO, Calif., July 30, 2018 /PRNewswire/ -- Noona Healthcare, a leading Oncology Decision Support platform, announced today the initiation of a collaboration with Duke University School of Medicine to assess the long-term impact of immuno-oncology (IO) therapies on cancer patients who have experienced stable and durable remissions.
Duke has a distinguished track record in clinical research, led by the Duke Clinical Research Institute and academic faculty, to support the FDA in assessing the quality of real-world data.
"We realize that IO long-term survivors, while often benefiting from these innovations, are, at the same time, facing long-term uncertainties associated with potential side effects," says Kim Lyerly, a George Barth Geller Professor at Duke University School of Medicine.
"There is a significant amount of quality investigation going on to decipher the molecular causality of a response, or lack thereof, to a checkpoint inhibitor like PD1 and other immuno-oncology therapies. In addition, these therapies display a non-conventional set of adverse events and the patterns of manifestation over time also are different from standard chemotherapies," says Dr. Claudio D'Ambrosio, CCO of Noona.
The Noona platform will generate research-grade, high-quality data on a comprehensive and scientifically validated list of symptoms associated with IO therapies. The goal will thus be to infer causality or correlate with other datasets such as genetic and proteomic cancer signatures.
"We are inspired and excited to partner with Professor Kim Lyerly at Duke to explore how electronic patient reported outcomes can monitor subtle symptoms and thus help decipher the long-term quality of life, functioning, and well-being of an increasing number of cancer survivors," says Founder and CEO of Noona, Jani Ahonala.
Noona is partnering with the world's leading life science oncology organizations to answer critical questions about optimal usage of cancer drugs in the real-world clinical practice and the impact on the healthcare system's budgets.
Phone: +358 45 1566 005